Abstract | BACKGROUND: AIMS: PATIENTS AND METHODS: RESULTS: Cases and controls were similar with respect to pre-treatment with terlipressin. The hepatorenal syndrome recurrence probability was the same in the two groups (cases and control: 9/10, 90%, p=ns). No significant differences were found between cases and controls with respect to serum creatinine (1.9+/-0.1mg/dl vs. 2+/-0.2mg/dl), blood creatinine clearance (28+/-5ml/min vs. 24+/-5ml/min), urinary sodium excretion (12+/-6mequiv./d vs. 19+/-4mequiv./d) and PRA levels (17+/-3ng/ml/h) vs. 20+/-3ng/ml/h) after terlipressin withdrawal (p=ns). CONCLUSIONS:
|
Authors | C Alessandria, W Debernardi-Venon, M Carello, S Ceretto, M Rizzetto, A Marzano |
Journal | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
(Dig Liver Dis)
Vol. 41
Issue 4
Pg. 298-302
(Apr 2009)
ISSN: 1878-3562 [Electronic] Netherlands |
PMID | 19158001
(Publication Type: Journal Article)
|
Chemical References |
- Vasoconstrictor Agents
- Lypressin
- Midodrine
- Terlipressin
|
Topics |
- Case-Control Studies
- Drug Administration Schedule
- Female
- Hepatorenal Syndrome
(prevention & control)
- Humans
- Lypressin
(analogs & derivatives, therapeutic use)
- Male
- Middle Aged
- Midodrine
(therapeutic use)
- Prospective Studies
- Secondary Prevention
- Terlipressin
- Treatment Outcome
- Vasoconstrictor Agents
(therapeutic use)
|